NADH:ubiquinone oxidoreductase (complex I) deficiency is amongst the most encountered defects of the mitochondrial oxidative phosphorylation (OXPHOS) system and is associated with a wide variety of clinical signs and symptoms. Mutations in complex I nuclear structural genes are the most common cause of isolated complex I enzyme deficiencies. The cell biological consequences of such mutations are poorly understood. In this paper we have used blue native electrophoresis in order to study how different nuclear mutations affect the integrity of mitochondrial OXPHOS complexes in fibroblasts from 15 complex I-deficient patients. Our results show an important decrease in the levels of intact complex I in patients harboring mutations in nuclear-encoded complex I subunits, indicating that complex I assembly and/or stability is compromised. Different patterns of low molecular weight subcomplexes are present in these patients, suggesting that the formation of the peripheral arm is affected at an early assembly stage. Mutations in complex I genes can also affect the stability of other mitochondrial complexes, with a specific decrease of fully-assembled complex III in patients with mutations in NDUFS2 and NDUFS4. We have extended this analysis to patients with an isolated complex I deficiency in which no mutations in structural subunits have been found. In this group, we can discriminate between complex I assembly and catalytic defects attending to the fact whether there is a correlation between assembly/activity levels or not. This will help us to point more selectively to candidate genes for pathogenic mutations that could lead to an isolated complex I defect.
INTRODUCTION
Mitochondrial diseases are a heterogeneous group of multisystemic disorders mostly caused by the dysfunction of one or more enzyme complexes of the oxidative phosphorylation (OXPHOS) system. NADH:ubiquinone oxidoreductase (complex I) deficiency is a frequently diagnosed defect of the mitochondrial OXPHOS system generally associated with severe metabolic disorders of childhood, like progressive encephalomyopathy, leukodystrophy or Leigh syndrome. Patients show a wide spectrum of clinical presentations and many die very young because of a fatal dysfunction of tissues with high metabolic energy rates (1) .
Mammalian complex I is an approximately 980 kDa holoenzyme that consists of two functional parts: a catalytic peripheral arm that protrudes into the matrix, and a membrane arm for proton translocation, which is embedded in the mitochondrial inner membrane (figure 1).
Complex I is made up of at least 39 different structural proteins encoded by the nuclear genome and 7 subunits encoded by the mitochondrial DNA (2) . By using mild chaotropic detergents the complex has been resolved into various subcomplexes, each containing a different subunit composition (2) . Although in some cases mitochondrial DNA mutations have been described to cause a complex I deficiency, they only account for a small percentage of the total number of complex I-deficient patients. In the majority of these patients mutations in nuclear genes are expected. The identification and genetic characterization of 45 human complex I nuclear structural genes has been completed (1, 2). As a result of an extensive mutation detection program at our center in a research cohort of 24 patients presenting with an isolated complex I deficiency, pathogenic mutations were found in five complex I nuclear genes: NDUFS2 (3), NDUFS4 (4, 5) , NDUFS7 (6) , NDUFS8 (7) and NDUFV1 (8) . Later, other groups detected new mutations in NDUFS4 (9, 10) , NDUFS1 (11) , NDUFV1 (11) and NDUFV2 (12, 13) . Except for NDUFS4, all the pathogenic mutations are located in the structural core subunits that are highly conserved from bacteria to mammals (14) . In the remaining patients no mutations have been identified after screening all complex I structural genes, thus the genetic defect leading to an isolated complex I deficiency must be found in nuclear genes encoding regulatory proteins of complex I biogenesis or activity. The exact mechanisms by which these mutations affect the function of mitochondrial complex I remain unclear. Studies in Yarrowia lipolytica have shown that mutations in the genes encoding subunits PSST and TYKY (NDUFS7 and NDUFS8 homologues, respectively) affected electron transport by altering complex I in vitro kinetics, resulting in a catalytically impaired complex I (15) . Similarly, mutational analyses of the yeast NDUFS2 homologue revealed its central role (together with PSST and TYKY) in the catalytic core for ubiquinone reduction at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from (16) . A 5-bp duplication in the NDUFS4 gene destroys a cAMP-dependent consensus phosphorylation site, abolishing complex I activity in a Leigh syndrome patient (17) . It has been recently demonstrated that patients with genetic alterations in NDUFS4 show low levels of mitochondrial complex I together with an accumulation of an intermediate subcomplex (18) , suggesting defects in complex I assembly or stability. To better characterize complex I deficiencies, we used western blotting in combination with sucrose gradient centrifugation in our patient cohort (19) . Differences found in the relative subunit composition of complex I in these patients seemed to depend on the gene mutated, suggesting that distinct pathogenic mutations within the same gene could lead to a similar assembly defect. Furthermore, a severe disturbance in complex I assembly was confirmed in one patient harboring an unknown nuclear mutation (19) .
In order to study how these mutations affect the integrity of mitochondrial OXPHOS complexes, we have now extended the biochemical studies by using blue native gel electrophoresis (BN-PAGE) (20) . Here we report our results in cultured skin fibroblasts from 15 complex I-deficient patients harboring mutations in complex I-related nuclear genes (table   1) . Six patients with known mutations in complex I subunits show low relative amounts of fully-assembled complex I that correlate with low levels of complex I activity detected in-gel, suggesting that complex I assembly or stability is compromised. By two dimensional BN-PAGE, different patterns of complex I sub-products are detected in patients with different mutated genes. Two patients harboring unknown nuclear mutations present such low complex I activity/assembly levels, suggesting that the genetic defect should be found in a new complex I subunit or assembly factor. The remainder seven patients show almost normal levels of the fully-assembled holoenzyme with low complex I activities, compatible with a catalytic defect in which a mutation could be found in a factor participating in the activation of complex I. Finally, we have analyzed how the different mutations in complex I genes affect the stability of other OXPHOS complexes, demonstrating a specific decrease of intact mitochondrial complex III in patients with mutations in NDUFS2 and NDUFS4. 
RESULTS

The integrity of human mitochondrial complex I is altered by mutations in nuclearencoded subunits
Mitochondria isolated from cultured skin fibroblasts of complex I-deficient patients (table 1) in which mutations have been described in subunits NDUFS2 (3), NDUFS4 (5, 21), NDUFS7 (6) and NDUFS8 (7) were run under native conditions in a BN-PAGE system and subjected to a complex I in-gel activity assay ( figure 2A ). As expected, low complex I activities were confirmed in all the patient samples when compared to control levels. A second activity below 440 kDa is normally observed in all samples tested, which include rho zero cells (unpublished data) and it could correspond to other NADH dehydrogenases present in mitochondria. A duplicate gel was blotted and incubated with antibodies raised against the complex I subunits NDUFA9 and NDUFS3 (figures 2B and 2C, respectively). Decreased levels of fully-assembled complex I were observed in all cases, which correlate with the low complex I activities found in the patients. These results suggest that disturbances in the assembly pathway or in the stability of mitochondrial complex I are the direct cause of the decreased activity levels. This effect seemed to be more pronounced in two patients with mutations in NDUFS8 (patient 1) and NDUFS2 (patient 3). Moreover, patients 5 and 6 carrying mutations in the NDUFS4 gene accumulated high levels of a lower molecular weight subcomplex (~800 kDa, gray arrow) that showed no complex I activity in figure 2A , as has been recently described (18) . The same product was observed in three additiona l patients with different mutations in NDUFS4 (data not shown). Other subcomplexes containing subunit NDUFS3 were commonly present in patients and control samples (figure 2C, small black arrows). Surprisingly, patient 3 (P229Q mutation in NDUFS2) repeatedly showed a band at a position higher than complex I (figure 2C, dashed arrow). It also appeared in the NDUFS4 patients 5 and 6 under different electrophoretic conditions (data not shown). In patient 3, this band was more intense than the one corresponding to the fully-assembled complex (estimated ratio 2:1) and it could correspond to the presence of mitochondrial supercomplexes I 1 III 2 or When we compared the ratios between native mitochondrial complexes, it appeared that the levels of the fully-assembled complex III dimer (~600 kDa) were clearly decreased in the patients harboring different mutations in NDUFS2 (patients 3 and 4) and NDUFS4 (patients 5 and 6), were slightly decreased by the mutation in NDUFS7 (patient 2), but not affected by the mutation in NDUFS8 ( figure 2E ). This result supports the idea of a physical interaction between both complexes. In agreement with this, a combined complex I+III deficiency has been described for three patients carrying mutations in the NDUFS4 gene (5, 21) . A similar reduction in the levels of complex III was observed in two out of three additional patients harboring different mutations in NDUFS4, making it a total of four patients. All these patients harbour missense mutations leading to premature stop codons in the central part of the protein. In the remainder patient with normal assembled complex III (4), the mutation is located very near to the carboxy terminus of the protein, suggesting that this region is important for the activity of complex I but not relevant for the stability of mitochondrial complex III (Ugalde et al., manuscript in preparation). Because all the patients showed normal cytochrome c oxidase (COX) enzymatic activities and the enzymatic values for complex I were calculated relative to COX (table 1), the antibody against COX I sub unit was also used to normalize for the expression levels of mitochondrial complex IV (figure 2D).
Fully-assembled COX levels were slightly increased in patients 4, 5 and 6 when compared to the control, but this is probably due to differences in sample loading in this particular experiment.
The signals from the blots were quantified and the complex I/complex IV and complex III/complex IV ratios were used as numerical values for the expression levels of fullyassembled complex I and III, respectively (table 2 ). An apparent lack of correlation between the residual complex I enzymatic activities shown in table 1 and the amount of fullyassembled complex I quantified in table 2 occurred in some patients. For instance, patients 1 and 2 presented a similar complex I activity but the differences in the amount of complex I calculated in table 2 were bigger (7 and 50%, respectively). These differences might come from the mitochondrial extraction method used in each assay. For the biochemical activity measurements, differential centrifugation in glucose gradient was used, whereas for the BNE assay, digitonin extraction was used. Although digitonin is considered a mild detergent, it could enhance the disruption of the complex and the loss of complex I activity under circumstances that would promote the loss of stability of the complex (such as certain mutations in complex I subunits). If this is the case, this treatment does not seem to affect the levels of fully-assembled complex I in control fibroblasts.
Reversibly, patients with mutations in NDUFS2 and NDUFS4 showed a relatively important decrease of assembled complex III levels with very limited or no complex III enzymatic defect. Possibly the reduction in the levels of fully-assembled complex III is not sufficient to reach the threshold necessary to provoke a marked decrease on complex III activity, as it has been shown in a parkinsonism-related complex III deficiency (23) .
Distinct patterns of low molecular weight subcomplexes in patients with mutations in nuclear structural genes
To study in more detail how mutations in nuclear genes affected complex I assembly or stability, mitochondrial native (sub)complexes were separated in a second dimension SDS-PAGE system, blotted and incubated with antibodies against three complex I subunits: NDUFS3, localized in the peripheral arm and NDUFS5 and NDUFA9, localized in the peripheral and membrane arm boundary (figure 3). Three different effects were observed: (i) the repeated presence of lower amounts of fully-assembled complex I in patients' fibroblasts relative to controls, (ii) different patterns of low molecular weight subcomplexes that contain the NDUFS3 subunit and (iii) similar accumulation of an approximately 800 kDa subcomplex in patients with different mutated genes. These results confirm that the assembly and/or stability of mitochondrial complex I is severely affected by these mutations. The most dramatic effects were observed in the two patients with a heterozygous P79L/R102H mutation in the NDUFS8 subunit and with a homozygous P229Q mutation in NDUFS2 (not shown), where the signals for complex I subunits were almost undetectable. In all the patients NDUFS3-containing subcomplexes below 450 kDa accumulated, probably indicating that the formation of the peripheral arm is interrupted at very early stages of the assembly process.
Subunits NDUFS5 and NDUFA9 were mostly present in the ~800 kDa subcomplex, suggesting their incorporation at a later stage of complex I assembly. According to the results obtained in the first dimension, the accumulation of this late subcomplex is especially abundant in patients harboring mutations in the NDUFS4 gene (figure 3, lower panel).
Differences in catalytic versus assembly defects in patients harboring unknown mutations in nuclear genes
The same analysis was extended to 9 fibroblast cell lines from patients in which mutations have been discarded in nuclear and mitochondrial complex I structural genes (24) . Again, a complex I deficiency was confirmed in all the patients by a complex I in-gel activity assay (figure 4A). This decrease was more clearly noticeable when the band corresponding to complex I was normalized by the unspecific NADH dehydrogenase activity (figure 4A).
However, a complex I assembly/activity correlation was only found in patients 11 and 15 (figure 4B). In these cases the levels of fully-assembled complex I were very low and the levels of complex I activity were almost undetectable, suggesting an assembly defect as the primary cause of the decreased complex I activity. A lower molecular weight subcomplex also accumulated in patient 15 (figure 4B, gray arrow). Remarkably, patient 11 is the same in which an assembly defect was previously described by other means (19) . These data indicate that these two patients are good candidates for carrying mutations in a yet unknown complex I subunit or assembly factor. In the rest of this second group of patients complex I activities were low but the levels of fully-assembled complex I were normal, so the impairment of complex I activity is most probably due to a catalytic defect. The pattern and expression levels of native complexes III (figure 4C) and IV (not shown) were also analyzed, but no significant differences were detected between patients and controls.
DISCUSSION
Complex I deficiency comprises a number of clinically heterogeneous disorders of energy metabolism of which Leigh (or Leigh-like) syndrome is the most commonly diagnosed.
Unlike complex IV-deficient Leigh syndrome patients, in whom mutations have been mostly found in complex IV assembly factors such as SURF1 or SCO2, all mutations responsible for complex I deficiencies detected so far are located in complex I structural genes (25, 26) .
Patients with mutations in the complex I nuclear-encoded subunits NDUFS4, NDUFS7 and NDUFS8 plus, in our hands, approximately 50% of the patients in whom no mutations have been found yet, present with this devastating disorder (see table 1 ). Mutations found in the NDUFS2 gene have been specifically associated with hypertrophic cardiomyopathy and encephalomyopathy (3). Despite of genetic and clinical differences, in these patients there seems to be a common pathogenic mechanism leading to complex I or IV deficiencies that would involve a problem in the proper assembly or stabilization of the mitochondrial OXPHOS complexes. This in turn would lead to a decrease of OXPHOS activities and to structural changes in the mitochondrial inner membrane that subsequently could induce proton leakage, accumulation of toxic reactive oxygen species and release of apoptoticinducing factors.
According to this hypothesis, it has been recently demonstrated that complex Ideficient Leigh syndrome patients with genetic alterations in NDUFS4 or in the mitochondrial ND6 gene show low levels of native mitochondrial complex I together with an accumulation of lower intermediate assemblies (18, 27) . In rodent cells, complex I assembly and activity are affected by the lack of the NDUFA1-homologue subunit, MWFE (28) . In Neurospora crassa, complex I nuclear-encoded sub units play a central role of in the assembly and function of the holoenzyme (29) . In this paper we show that in six complex I-deficient patients where mutations in nuclear subunits have been found, complex I assembly and/or stability are severely compromised. Decreased levels of fully-assembled complex I correlate with the low complex I activities found in the patients, suggesting an assembly/stability defect as the primary pathogenic mechanism. To explain the causes we must take into account different factors, like the position and conservation of the mutations, the localization of the mutated subunits within the complex and the individual role of each subunit within the overall function of complex I. All the mutations are found in highly conserved aminoacid positions during evolution, but maybe some positions are functionally more relevant than others and provoke a more dramatic complex I defect. All the mutations analyzed are located in subunits forming the peripheral arm of the complex, therefore these mutations are expected to affect crassa and Y. lipolytica have shed light on the precise role of the core subunits. The most evident complex I defect was found in patients with P79L/R102H aminoacid changes in NDUFS8 and a P229Q substitution in NDUFS2, in whom native complex I was almost undetectable. The homologues of NDUFS7 and NDUFS2 have been described in Y.lipolytica to form the catalytic core for ubiquinone binding, a process in which NDUFS8 is also involved (16) . Reconstruction in Y. lipolytica of the human pathogenic mutations found in the NDUFS7 and NDUFS8 genes did not lead to an impaired complex I assembly but only to a complex I catalytic defect (15) . The same occurred with mutations in highly conserved residues of the NDUFS7 and NDUFS2 homologues (30, 31) . However, disruption of any of these three subunits in N. crassa showed impaired assembly of the peripheral arm, accumulation of the membrane arm and a consequent catalytic defect (32, 33, 34) . The differences found in complex I defects between our complex I-deficient patients and the yeast model give evidence of the necessary precaution that must be taken when mimicking human physiological conditions in lower species. All our patients with mutations in NDUFS4 showed also a marked decrease in the levels of fully-assembled complex I together with high levels of a defective subcomplex of ~800 kDa not present in controls, as already described (18) .
Additionally, the presence of lower bands between ~100-450 kDa containing complex I NDUFS3 subunit was detected both in control and all patient samples. These subcomplexes possibly correspond to assembly intermediates from the pathway recently proposed for complex I assembly (35) . In a second dimension, distinct patterns of lower molecular weight (18) . These results suggest that NDUFS4 would be incorporated at this late stage in the assembly process, as it has been reported (35) and that the lack of NDUFS4 would hamper the next step in the formation of fully-assembled complex I. The possibility also exists that the accumulation of lower molecular weight subcomplexes in these patients could not be only due to an assembly defect or to a lower rate of incorporation of the different subunits into the complex, but also to a lower complex I stability and its consequent disruption. Additional experiments must be performed in order to reach definitive conclusions.
In the remainder complex I-deficient patients ha rboring unknown mutations, catalytic versus assembly (or stability) defects have been easily distinguished by BN-PAGE. Two patients show a similar complex I assembly defect as established in the patients carrying mutations in nuclear-encoded subunits. Mutations in complex I subunits have been discarded in 45 out of the 46 complex I subunits, but the last of these subunits remains to be identified (2) . These two patients are candidates to carry mutations either in this complex I subunit or in a complex I assembly factor. Our identification of the human homologue of a N. crassa complex I assembly protein, CIA30, proves the existence of such factors (36) . Unfortunately, no disease-causing mutations have been found in any of these genes yet. In the rest of this second group of patients the levels of fully-assembled complex I are normal. The impairment in complex I activity cannot be explained by a defect in complex I assembly but to a pure catalytic defect, suggesting a different pathogenic mechanism leading to an isolated complex I deficiency. In these cases, mutations should be found in nuclear genes that regulate crucial steps in the activation of mitochondrial complex I. Examples of such candidate genes could be found in proteins involved in the phosphorylation of complex I subunits that could participate in the complex I activation/inactivation transition process, like mitochondrialspecific isoforms of c-AMP dependent kinases or phosphatases (37, 38) . In support of this, it has been shown in different species that mitochondrial complex I reversibly alternates between an active and a de-activated conformation that probably depends on the cell respiratory status (39, 40, 41) .
We have finally analyzed how these mutations affect the stability of native mitochondrial complexes III and IV in our patient group. In different experiments, the steadystate levels of fully-assembled complex IV did not vary substantially in these patients when compared to controls. However, the levels of the native complex III dimer were clearly decreased in the patients harboring mutations in NDUFS2 and NDUFS4, but not significantly altered by the mutations in NDUFS7 or NDUFS8 genes, or in any patient with unknown mutations in nuclear genes. This finding is in agreement with the combined complex I+III deficiency described for three patients carrying mutations in the NDUFS4 gene (5, 21).
Reversibly, a specific mutation in cytochrome b has been found to lead to a combined complex III+I deficiency in a patient with progressive exercise intole rance (42) . These results suggest a physical interaction between complexes I and III that could be mediated through these subunits. Experimental evidence supports this idea. The association of the mitochondrial respiratory chain complexes into higher supramolecular structures called supercomplexes seems to be well established in different organisms, including mammals (43) . In Y. lipolytica, the ubiquinone-binding 49 kDa subunit (homologue of NDUFS2) seems to be located in an external position near the tip of the peripheral arm (44) . By cross-linking studies, a direct interaction between the homologues of NDUFS2 and NDUFS4 (49 kDa and 18 kDa subunits, respectively) has been observed in bovine (45) . It would explain the similar phenotypes found in patients with mutations in these two genes. In these patients carrying mutations in NDUFS2 or NDUFS4, the decreased stability of mitochondrial complex III is accompanied by a slight or no reduction of complex III activity. This could be explained by internal compensatory activation mechanisms or by the fact that a loss of bigger amounts of assembled complex III could be necessary before getting a considerable decrease of complex III activity, as it has been suggested in cybrid clones harboring increasing amounts of mutant cytochrome b (23).
Finally, the first report demonstrating that complex I mutations interfere with the function or assembly of other OXPHOS complexes has been recently described in a Caenorhabditis elegans model (electronic manuscript, 46). Summarizing, by BNE we have been able to differentiate catalytic versus assembly/stability defects in complex I-deficient patients and to study the effects of these mutations on the stability of other mitochondrial OXPHOS complexes. Using this technique will not only expand the cell biological knowledge of the mitochondrial energy metabolism, but it will also be useful as an additional tool to improve the pre-and postnatal diagnostic possibilities in patients with a mitochondrial complex I deficiency. (3, 5, 6, 7, 21, 24, 47) .
MATERIALS AND METHODS
Patients
Cell Cultures
Fibroblasts were obtained from skin biopsies and cultured in M199 medium (Life Technologies) supplemented with 10% fetal calf serum (FCS) and 100 IU/ml penicillin and 100 IU/ml streptomycin.
Complex I assembly and in-gel activity studies
One and two-dimensional blue native gel electrophoresis (BN-PAGE) and mitochondrial complex I in-gel activity assays were performed with digitonin-isolated mitochondria from patients' fibroblasts as previously described (48 To calculate the expression levels of complexes I and III, three independent blue native blots were quantified and the values normalized to those obtained from complex IV. Values below the normal expression range are highlighted in bold characters.
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